Santhera expands Biomedica pact to distribute AGAMREE in Central Asia, Caucasus

• Santhera expanded its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone) to cover five additional Central Asia and Caucasus markets.
• Biomedica will distribute the Duchenne muscular dystrophy therapy in Georgia, Kazakhstan, Belarus, Azerbaijan, Uzbekistan for patients aged 2 and older.
• Santhera will receive a percentage of net sales under the same terms as the original October 2025 distribution agreement.
• The added territories cover about 2,000 Duchenne muscular dystrophy patients, where treatment has largely relied on standard corticosteroids.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Santhera Pharmaceuticals Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130100PRIMZONEFULLFEED1001212409) on July 13, 2026, and is solely responsible for the information contained therein.